Alectos Therapeutics Announces FDA Orphan Drug Designation

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Alectos Therapeutics Announces FDA Orphan Drug Designation for MK-8719: An Investigational Small-molecule OGA Inhibitor for Treatment of Progressive Supranuclear Palsy

VANCOUVER, BRITISH COLUMBIA, April 20, 2016 (GLOBE NEWSWIRE) -- Alectos Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to OGA inhibitor MK-8719 for the treatment of progressive supranuclear palsy (PSP). Alectos also announced completion of a Phase 1 clinical trial in its ongoing collaboration with Merck, known as MSD outside the U.S. and Canada. This collaboration aims to develop agents that modulate the O-GlcNAcase (OGA) enzyme as a disease-modifying therapy for treatment of various neurodegenerative diseases. This follows the achievement of a previously undisclosed preclinical research milestone in 2012 under the same agreement.

“We are gratified that our collaboration with the exceptional team at Merck has progressed to clinical testing of this novel disease-modifying therapeutic approach for patients affected by PSP and other tauopathies” Ernest McEachern, Ph.D., CEO of Alectos, said. “This is an important validation of our scientific leadership in the area of OGA modulators, and we look forward to working with Merck to realize the full value of this novel mechanism for a range of neuroscience disorders”.

MK-8719 is an orally available potent and selective small-molecule OGA inhibitor planned for evaluation for the treatment of PSP. Like Alzheimer’s disease, PSP belongs to the family of neurodegenerative disorders known as tauopathies; these diseases are associated with the formation and progressive spread of toxic oligomers of tau protein in the brain. Preclinical data that has been independently confirmed by several groups provides evidence that OGA inhibition reduces tau pathology and associated neurodegeneration. Extensive preclinical validation, the oral bioavailability of MK-8719, and the use of biomarkers including a novel OGA PET ligand to establish target engagement in the brain set MK-8719 apart from previous efforts to treat tau related disease.

“Merck has a strong commitment to neuroscience.” said Darryle D. Schoepp, Ph.D., Vice President, Neuroscience Discovery, Merck Research Laboratories. “We are pleased to have advanced this first in class molecule in collaboration with Alectos and look forward to testing this novel mechanism in patients".

Clinical development of MK-8719 was initiated with a single ascending dose Phase 1 study in healthy adult subjects to evaluate the safety, tolerability, and plasma pharmacokinetics of MK-8719. Single doses of MK-8719 up to 1200 mg were administered revealing favorable human pharmacokinetics and pharmacodynamic effects of OGA inhibition in blood. Brain OGA target engagement has also been assessed with a directed PET ligand in additional Phase 1 work that will support dose selection for efficacy studies. These data support further clinical development of MK-8719 and investigation of safety/tolerability and efficacy in PSP patients.

About Orphan Drug Designation

The FDA Orphan Drug Designation program provides a special status to drugs and biologics intended to treat, diagnose or prevent so-called orphan diseases and disorders that affect fewer than 200,000 people in the U.S. This designation provides for a seven-year marketing exclusivity period against competition, as well as certain incentives, including federal grants, tax credits and a waiver of PDUFA filing fees. The approval of an orphan designation request does not alter the standard regulatory requirements and process for obtaining marketing approval.

About Progressive Supranuclear Palsy

PSP is a progressive neurodegenerative disorder, with an estimated worldwide incidence of six per 100,000 people. The disease affects approximately 20,000 individuals in the U.S. and 35,000 individuals in Europe. The most common features of PSP are loss of balance, blurred vision, and problems controlling eye movement. Other PSP symptoms, such as slowed movement and behavioral or cognitive changes, are similar to other brain disorders, particularly Parkinson's disease. The course of PSP is progressive and predisposes individuals to serious complications, such as choking, pneumonia, head injury and fractures caused by falls. Currently, there are no approved treatments for PSP. It is one of more than 20 different neurodegenerative disorders, including Alzheimer’s disease, that are characterized by abnormalities in the brain protein tau. For more information on PSP, please visit www.psp.org.

About Alectos Therapeutics Inc.

Alectos Therapeutics is a private pharmaceutical company dedicated to the discovery and development of novel small-molecule drugs for human disease. Alectos was founded in 2007 as a spin-off company based on technologies initially discovered in the laboratory of Professor David Vocadlo at Simon Fraser University, who also serves as Alectos CSO. For more information, please visit our website at www.alectos.com. Digital images are available by request.

Contact Ernest McEachern, Ph.D. President & CEO Alectos Therapeutics Inc. Phone: 604-628-7129 Email: info@alectos.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 309

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 234

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 459

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 59

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 328

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 322

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 0

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 393

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 290

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading

Top 5 Most Recently Viewed Articles

La Française des Jeux Implements Squeeze-Out Rights on Kindred Group

Updated Category News Views 69

La Française des Jeux Implements Squeeze-Out Rights on Kindred Group Kindred Group plc, one of the major players in the online gambling sector, finds itself in the spotlight following a recent notice from La Française des Jeux (FDJ). The notification signifies an important step, reflecting the dynamic nature of the industry's landscape. Understanding the Squeeze-Out...

Continue Reading
Inspirato Set to Reveal Q3 2024 Financial Results Soon

Updated Category News Views 85

Upcoming Q3 2024 Results Announcement Inspirato Incorporated (NASDAQ: ISPO), recognized as a premier luxury vacation club, has scheduled its release of financial and operating results for the third quarter of 2024. This announcement is anticipated to take place after market closure on Monday. As an entity that redefines luxury travel experiences, this news is particularly...

Continue Reading
Empowering the Future: Leadership Course at Milton Hershey School

Updated Category News Views 202

Leadership Development for Milton Hershey School Students Milton Hershey School (MHS) offers its high school students a remarkable opportunity to engage in a college-level summer course focused on leadership. This initiative is particularly designed for students advancing into their junior and senior years, allowing them to enrich their academic profile while developing...

Continue Reading
Viavi Solutions Shows Promising Growth Amid Market Pressures

Updated Category News Views 330

Viavi Solutions Adjusts Forecasts Following Financial Insights Recently, an analyst from Rosenblatt made notable adjustments to the financial outlook for Viavi Solutions (NASDAQ: VIAV), raising the price target from $8.25 to $10.50. The update came after reviewing the firm’s earnings report for the first quarter of fiscal year 2025, which revealed that revenue and...

Continue Reading
180 Degree Capital Corp. Evaluates Proposal from Source Capital

Updated Category News Views 197

180 Degree Capital Corp. Evaluates Source Capital Proposal 180 Degree Capital Corp. (NASDAQ: TURN) is committed to ensuring that its shareholders are informed and adequately represented when it comes to corporate developments. Recently, the company’s Board of Directors took a significant step by analyzing a non-binding proposal put forth by Source Capital. The proposal,...

Continue Reading